Temporal Trends in Grade 3/4 Adverse Events and Associated Costs of Nivolumab Plus Cabozantinib Versus Sunitinib for Previously Untreated Advanced Renal Cell Carcinoma

Autor: Daniel M. Geynisman, Mauricio Burotto, Camillo Porta, Cristina Suarez, Maria T. Bourlon, Stephen Huo, Viviana Del Tejo, Ella X. Du, Xiaoran Yang, Keith A. Betts, Toni K. Choueiri, Bradley McGregor
Přispěvatelé: Institut Català de la Salut, [Geynisman DM] Department of Hematology/Oncology, Fox Chase Cancer Center, Philadelphia, PA, USA. [Burotto M] Oncology Department, Bradford Hill Clinical Research Center, Santiago, Chile. [Porta C] Interdisciplinary Department of Medicine, University of Bari ‘A.Moro’ and Division of Oncology, A.O.U. Consorziale Policlinico di Bari, Bari, Italy. [Suarez C] Servei d’Oncologia Mèdica, Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain. Vall d’Hebron Hospital Universitari, Barcelona, Spain. [Bourlon MT] Department of Hemato-Oncology, Urologic Oncology Clinic, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico. [Huo S] Worldwide Health Economics and Outcomes Research-US Market, Bristol Myers Squibb, Princeton, NJ, USA, Vall d'Hebron Barcelona Hospital Campus
Rok vydání: 2022
Předmět:
Pyridines
neoplasias::neoplasias::neoplasias por localización::neoplasias urogenitales::neoplasias urológicas::neoplasias renales::carcinoma de células renales [ENFERMEDADES]
terapéutica::terapéutica::farmacoterapia::protocolos antineoplásicos::terapéutica::farmacoterapia::protocolos de quimioterapia antineoplásica combinada [TÉCNICAS Y EQUIPOS ANALÍTICOS
DIAGNÓSTICOS Y TERAPÉUTICOS]
Otros calificadores::Otros calificadores::/farmacoterapia [Otros calificadores]
General Medicine
Other subheadings::Other subheadings::/drug therapy [Other subheadings]
Quimioteràpia combinada
Kidney Neoplasms
Nutrition Disorders
Fetge - Càncer - Tractament
Medicaments antineoplàstics - Efectes secundaris
Nivolumab
Therapeutics::Therapeutics::Drug Therapy::Antineoplastic Protocols::Therapeutics::Drug Therapy::Antineoplastic Combined Chemotherapy Protocols [ANALYTICAL
DIAGNOSTIC AND THERAPEUTIC TECHNIQUES
AND EQUIPMENT]
Neoplasms::Neoplasms::Neoplasms by Site::Urogenital Neoplasms::Urologic Neoplasms::Kidney Neoplasms::Carcinoma
Renal Cell [DISEASES]
Antineoplastic Combined Chemotherapy Protocols
Sunitinib
Humans
Pharmacology (medical)
Anilides
Carcinoma
Renal Cell
Zdroj: Scientia
ISSN: 1179-1918
Popis: Advanced Renal Cell Carcinoma; Adverse Events; Nivolumab Carcinoma de células renales avanzado; Eventos adversos; Nivolumab Carcinoma de cèl·lules renals avançat; Esdeveniments adversos; Nivolumab Background and Objectives Novel immunotherapy-based combination treatments have drastically improved clinical outcomes for previously untreated patients with advanced/metastatic renal cell carcinoma (aRCC). This study aimed to assess the temporal trends in grade 3/4 adverse event (AE) rates and associated costs of nivolumab plus cabozantinib combination therapy versus sunitinib monotherapy in previously untreated patients with aRCC. Methods Individual patient data from the CheckMate 9ER trial (nivolumab plus cabozantinib: N = 320; sunitinib: N = 320) were used to calculate the proportion of patients experiencing grade 3/4 AEs. AE unit costs were obtained from the United States (US) 2017 Healthcare Cost and Utilization Project (HCUP) and inflated to 2020 US dollars. Per-patient-per-month (PPPM) all-cause and treatment-related grade 3/4 AE costs over 18-months, temporal trends, and top drivers of AE costs were evaluated in both treatment arms. Results Overall, the proportion of patients experiencing grade 3/4 AEs decreased over time, with the highest rates observed in the first 3 months for the nivolumab plus cabozantinib and sunitinib arms. Compared with sunitinib, nivolumab plus cabozantinib was associated with consistently lower average all-cause AE costs PPPM [month 3: $2021 vs. $3097 (p < 0.05); month 6: $1653 vs. $2418 (p < 0.05); month 12: $1450 vs. $1935 (p > 0.05); month 18: $1337 vs. $1755 (p > 0.05)]. Over 18 months, metabolism and nutrition disorders ($244), laboratory abnormalities ($182), and general disorders and administration site conditions ($122) were the costliest all-cause PPPM AE categories in the nivolumab plus cabozantinib arm, and laboratory abnormalities ($443), blood and lymphatic system disorders ($254), and metabolism and nutrition disorders ($177) were the costliest in the sunitinib arm. Trends of treatment-related AE costs were consistent with all-cause AE costs. Conclusions Nivolumab plus cabozantinib was associated with lower costs of grade 3/4 AE management PPPM than sunitinib, which accumulated over the 18-month study period.
Databáze: OpenAIRE
Externí odkaz: